On April 21, 2022 Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders, reported that Dr. Milton Werner, Ph.D., the Company’s President & Chief Executive Officer will participate in a fireside chat at the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference on April 28, 2022 at 2:30pm ET (Press release, Inhibikase Therapeutics, APR 21, 2022, View Source;ophthalmology-conference-301530237.html [SID1234612882])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available for on-demand viewing under "News & Events" in the Investors section of the Company’s website, www.inhibikase.com. An archived replay of the webcast will be available for approximately 30 days. In addition, the Company recently hosted a virtual Key Opinion Leader investor event on April 20, 2022. A replay of the event can be accessed here.

On April 21, 2022 MaaT Pharma (EURONEXT: MAAT – the "Company"), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer reported on March 28th, 2022, the inclusion of the first patient in a pivotal Phase 3 clinical trial, potentially the last step of clinical development before marketing authorization, evaluating MaaT013 for the treatment of acute gastrointestinal Graft-versus-Host Disease (aGvHD), a serious complication following stem cell transplantation (Press release, MaaT Pharma, APR 21, 2022, View Source [SID1234612709]). Every year, more than 10,000 people are diagnosed in Europe and in the United States of America[1], and the prognosis for the patients with the most advanced form is poor with a mortality rate of up to 80%[2] in the first year. This new milestone for MaaT Pharma, the first Euronext-listed company developing microbiome-based therapies, builds on the success story of its founding partnership with INRAE initiated in 2014, in particular via the scientific support agreement[3] between MaaT Pharma, INRAE and Dr. Joël Doré, INRAE Research Director, Scientific Director of Métagénopolis, author of nearly 500 publications, and one of the world’s most cited authors in the microbiome sphere today.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the end of 2014, following a project development period as an entrepreneur-in-residence with Seventure Partners, Hervé Affagard, currently CEO, founded MaaT Pharma alongside Dr. Joël Doré, now MaaT Pharma’s Scientific Advisor. As early as 2015, MaaT Pharma and INRAE co-filed three patents, for which the Company now holds exclusive exploitation rights. These patents are also at the root of the development of the Company’s native products, MaaT013 and MaaT033, both currently in clinical trials.

"Microbiome science has been at the heart of my research for more than 30 years. INRAE has established itself first as a pioneer, then as an international center of excellence in the field. In 2021, for example, INRAE was the 5th largest academic player in the world in terms of microbiome-related patents. In my opinion, the rapid growth of MaaT Pharma, which has entered a Phase 3 clinical trial, perfectly illustrates the efficient and successful transition from pioneering science to innovative therapeutic development for the benefit of patients. Through my research, I hope to contribute to the fast emergence of a new medicinal modality, that takes into account the symbiotic relationship between human health and the microbiome," said Dr. Doré.

Following the advent of metagenomics[4], the research produced at INRAE on the gut microbiome has led to unprecedented results disrupting our understanding of the digestive ecosystem, and opening novel avenues for improving the health of millions of patients worldwide suffering from cancers, metabolic diseases, or inflammatory diseases to name just a few of the potential indications.

MaaT Pharma has developed a portfolio of three products since its creation including two currently in clinical phases. The Company has initiated five Phase 1 and Phase 2 clinical trials, consolidated its patent portfolio (including 13 international patent families), and raised a total of €83 million. The Company currently employs 45 people and MaaT013 has been administered to more than 100 people with aGvHD in a Phase 2 clinical trial and in an ongoing compassionate access program[5] in France.

Hervé Affagard, CEO and co-founder of MaaT Pharma commented, "Since our foundation, we have been looking to develop the microbiome ecosystem in France and have forged partnerships with medical and scientific centers of excellence as well as with renowned industrial players to develop the Company. In 2016, we launched our first clinical trial just 18 months after the company’s creation, and we have since strengthened our position as a pioneer in microbiome-based therapies in oncology. Our translational expertise allows us to rapidly transform science into groundbreaking and safe drug candidates, with the support of our scientific partners, to improve survival outcome for cancer patients."

The collaboration between these two pioneers continues to move forward with the formation of industry structures and the growth of national expertise in the microbiome space in Europe with the Alliance Promotion Microbiote (APM), of which both organizations are among the co-founders. APM is an association under the French law of 1901 and includes 25 private and public players (companies, clusters, research institutes, investment funds), of which Hervé Affagard was elected president in January 2022. APM aims to contribute to making France, a pioneering nation in microbiome research and engineering, into a European leader to meet the current and future challenges of this sector recognized in 2021 as a priority in the "Health Innovation Plan 2030 ".

[1] Source: Global Data GVHD Epidemiology Report, Jan 2020.
[2] Source: Essai REACH1
[3] Article L 531-8 and 9 of the French Research Code allowing the participation of research personnel in the creation of companies or in the activities of a company and the promotion of their work
[4] metagenomics: a method used to study the microbiome – Qin, J., Li, R., Raes, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65 (2010)
[5] Compassionate use programs allow the use of investigational drugs before they are authorized for marketing for patients with no treatment-options.

On April 21, 2022 Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, reported that it has been recognized by the Boston Business Journal as one of the Best Places to Work for the second year in a row (Press release, Surface Oncology, APR 21, 2022, View Source [SID1234612766]). Surface was among 20 companies selected in the "small" category with 50 to 99 Massachusetts-based employees.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are thrilled to be recognized once again as one of the Best Places to Work by the Boston Business Journal," said Rob Ross, M.D., chief executive officer at Surface Oncology. "At Surface, we are moving with urgency and passion to bring important new immunotherapies to people confronting cancer, and that shared mission is what unites our team and makes this such a special place to work. We remain committed to cultivating a diverse and dynamic culture built on our core values of courage, integrity, and community."

In 2022, more than 220 businesses across healthcare, technology, commercial real estate, and other industries participated in the Best Places to Work program. Through an independent survey, employees rated areas including job satisfaction, personal engagement, level of communication and resources, teamwork, retention, alignment with goals, and manager effectiveness.

Surface will be among 80 companies honored for creating outstanding work environments at a celebration on June 16, 2022, at the Boston Park Plaza and featured in a Best Places to Work edition of the Boston Business Journal to be published on June 17, 2022.

On April 21, 2022 Terran Biosciences, Inc. ("Terran"), a biotechnology platform company dedicated to the development of transformational therapies for neurological and psychiatric diseases, reported that has entered into an agreement with Sanofi SA ( " Sanofi") for exclusive worldwide rights to develop and commercialize two late-stage SNC portfolio assets (Press release, Sanofi, APR 21, 2022, View Source;_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc [SID1234612883]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These therapies generated four investigational new drug (IND) applications and more than 104 clinical studies involving more than 15,000 subjects in various CNS indications.

Terran plans to rapidly advance the development of these actives for neurological and psychiatric indications, including several novel applications where there is a high unmet medical need. This transaction represents the next key stage in the development of these promising assets.

The deal included an upfront payment, as well as typical milestones and royalties based on success. Specific financial terms of the deal were not disclosed.

"We are grateful to the team at Sanofi for entrusting us with the continued development of these late-stage therapies, which we believe have the potential to transform the paradigm of neuropsychiatry," said Dr. Sam Clark , Founder and CEO of Terran.

On April 20, 2022 Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, reported that Snehal Patel, CEO of Greenwich LifeSciences, will participate in the following upcoming investor, partnering, and scientific conferences (Press release, Greenwich LifeSciences, APR 20, 2022, View Source [SID1234612581]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright Global Investment Conference – May 23-26, 2022

The Company will be participating in the H.C. Wainwright Global Investment Conference in Miami, Florida with an in-person presentation and will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. The conference will feature leading industry keynote speakers and presenting companies, investor one-on-one meetings, and networking opportunities with attendees. For more information, please visit the conference website at: View Source

American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting – June 3-7, 2022

The Company will present 2 posters and 3 abstracts at the ASCO (Free ASCO Whitepaper) Annual Meeting in Chicago, IL and will meet with clinical sites and networks participating in the upcoming FLAMINGO-01 phase III clinical trial. Founded in 1964, ASCO (Free ASCO Whitepaper) is the world’s leading professional organization for physicians and oncology professionals caring for people with cancer. ASCO (Free ASCO Whitepaper) offers premier scientific events for oncology professionals, patient advocates, industry representatives, and major media outlets worldwide. The ASCO (Free ASCO Whitepaper) Annual Meeting program features poster presentations, poster discussion sessions, clinical science symposia, and dynamic education sessions about recent advancements in cancer research, treatment, and patient care. For more information, please visit the conference website at: View Source

Jefferies Healthcare Conference – June 8-10, 2022

The Company will be participating in the Jefferies Healthcare Conference in New York, NY with an in-person presentation and will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. This conference gathers leading executives, institutional investors, private equity investors, and venture capitalists to address investment opportunities and to discuss the current trends driving healthcare globally. Jefferies is one of the largest healthcare investment banking teams in the world with over 135 professionals worldwide based in New York, San Francisco, London and Hong Kong covering over 1010 companies.

BIO International Convention – June 13-16, 2022

The Company will be participating in the BIO International Convention in San Diego, CA with an in-person presentation and one-on-one partnering meetings. The convention attracts 15,000+ biotechnology and pharma leaders for one week of intensive networking including scheduled one-on-one meetings with senior business development executives seeking potential financial and strategic partners. For more information please visit: View Source

The Company also previously participated in the following events:

Susan G. Komen’s More Than Pink Luncheon – March 10, 2022

The Company was an event sponsor and invited members of the upcoming FLAMINGO-01 clinical trial team to participate in this Houston, Texas event. The second annual More Than Pink Luncheon celebrated the vision of Komen’s founders with the hope and increasing promise of a cure. Susan G. Komen is the world’s leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. Visit www.komen.org.

BIO-Europe Spring – March 28-31, 2022

The Company participated in the BIO-Europe Spring partnering event which includes international business development, therapeutic areas, startup innovations, digital health, and scheduled one-on-one meetings with regional and global pharma companies. For more information, please visit the conference website at: https://informaconnect.com/bioeurope-spring/

About FLAMINGO-01 and GLSI-100

FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2/neu positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial will be led by Baylor College of Medicine and will include US and international clinical sites from university-based hospitals and cooperative networks. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients will be randomized to GLSI-100 or placebo, and up to 100 patients of other HLA types will be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater. The trial is currently registered on clinicaltrials.gov and can be seen here. For future updates about FLAMINGO-01 please visit the Company’s clinical trial tab at View Source

About Breast Cancer and HER2/neu Positivity

One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 282,000 new breast cancer patients and 3.8 million breast cancer survivors in 2021. HER2/neu (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels.